Compare PED & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8M | 163.4M |
| IPO Year | 2012 | 2019 |
| Metric | PED | ARCT |
|---|---|---|
| Price | $14.33 | $15.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $30.00 | $24.11 |
| AVG Volume (30 Days) | 17.3K | ★ 1.4M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | $45,751,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $171.75 | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $5.50 |
| 52 Week High | $18.89 | $24.14 |
| Indicator | PED | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 71.39 |
| Support Level | $12.89 | $6.47 |
| Resistance Level | $16.70 | N/A |
| Average True Range (ATR) | 0.64 | 1.59 |
| MACD | 0.15 | 0.36 |
| Stochastic Oscillator | 85.29 | 78.16 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.